Publications by authors named "Nashwa M Elbaioumy"
BMC Complement Med Ther
September 2023
Article Synopsis
- Sorafenib is the only approved drug for treating hepatocellular carcinoma (HCC), and the study investigates the potential of amygdalin, known for its anticancer properties, to work synergistically with Sorafenib against HCC cells.
- Results show that amygdalin selectively kills HepG2 cancer cells while being less toxic to normal cells, and it works together with Sorafenib to enhance cell death through mechanisms involving cell cycle arrest and apoptosis.
- The study suggests amygdalin inhibits the AMPK enzyme, leading to the downregulation of the mTOR and BCL-2 pathways, providing a basis for further research into amygdalin as a promising alternative treatment for HCC.
